| 26.04 15:02 | dpa-AFX: Gilead Sciences Says FDA OK's Updated Label Of Biktarvy To Treat Pregnant People With HIV-1 |
| 26.04 14:07 | dpa-AFX: *GILEAD SCIENCES: FDA APPROVES BIKTARVY(R) LABEL UPDATE WITH DATA FOR PREGNANT ADULTS WITH HIV |
| 25.04 23:12 | dpa-AFX: Gilead Sciences Inc. Q1 Earnings Summary |
| 25.04 22:57 | dpa-AFX: *GILEAD SCIENCES Q1 LOSS/SHARE $3.34 VS. PROFIT $0.80 YEAR AGO |
| 25.04 12:03 | dpa-AFX: Gilead Sciences Q1 24 Earnings Conference Call At 4:30 PM ET |
| 02.04 13:46 | dpa-AFX: Nurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two Years |
| 02.04 13:30 | dpa-AFX: *NURIX THERAPEUTICS ANNOUNCES EXTENSION OF STRATEGIC COLLABORATION WITH GILEAD SCIENCES BY 2 YRS |
| 28.03 14:17 | dpa-AFX: Gilead's SNDA For Vemlidy Gets FDA Approval To Treat Chronic HBV Infection In Pediatric Patients |
| 28.03 13:34 | dpa-AFX: *GILEAD : FDA EXPANDS INDICATION FOR VEMLIDY TO TREAT CHRONIC HBV INFECTION IN PEDIATRIC PATIENTS AS YOUNG AS SIX |
| 28.03 12:34 | dpa-AFX: Gilead, Xilio Announce Exclusive License Agreement For Tumor-Activated IL-12 Program XTX301 |
| 28.03 12:06 | dpa-AFX: *GILEAD SCIENCES, XILIO THERAPEUTICS ANNOUNCE LICENSE AGREEMENT TO DEVELOP TUMOR-ACTIVATED IL-12 PROGRAM, XTX301 |
| 22.03 15:06 | dpa-AFX: Gilead Sciences Completes Acquisition Of CymaBay Therapeutics |
| 22.03 14:25 | dpa-AFX: *GILEAD SCIENCES COMPLETES ACQUISITION OF CYMABAY THERAPEUTICS FOR ABOUT $4.3 BLN IN TOTAL EQUITY VALUE |
| 11.03 13:54 | dpa-AFX: Gilead Sciences Announces Expiration Of HSR Waiting Period For CymaBay Tender Offer |
| 11.03 13:29 | dpa-AFX: *GILEAD SCIENCES - CYMABAY THERAPEUTICS DEAL RECEIVES U.S. ANTITRUST APPROVAL |
| 27.02 03:11 | dpa-AFX: Gilead Sciences : FDA Expands Biktarvy Indication For HIV Treatment |
| 12.02 22:09 | MÄRKTE USA/Wall Street nach Rekordjagd mit Gewinnmitnahmen |
| 12.02 18:31 | MÄRKTE USA/Wall Street nimmt Rekordjagd wieder auf |
| 12.02 15:52 | MÄRKTE USA/Stagnation - Börse pausiert nach Rekordjagd |
| 12.02 14:48 | dpa-AFX: Gilead To Acquire CymaBay; To Enhance Revenue Growth Upon Approval Of Seladelpar |
|
|
